Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 6/20 | 0.54 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.54 |
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | CHKA | P35790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29972660 | 0.83 | ABCB1 (0.50) | ABCB1ABCC1ABCG2DHFRREV1 | |
| SCHEMBL24761130 | 0.83 | ABCB1 (0.50) | ABCB1ABCC1ABCG2DHFRREV1 | |
| SCHEMBL10383284 | 0.82 | ABCB1 (0.74) | ABCB1ABCC1ABCG2KMT2AREV1 | |
| SCHEMBL382900 | 0.80 | ABCB1 (0.64) | ABCB1ABCC1ABCG2KMT2AREV1 | |
| SCHEMBL29972571 | 0.79 | ABCB1 (0.47) | ABCB1ABCC1ABCG2DHFRREV1 | |
| SCHEMBL24761540 | 0.79 | ABCB1 (0.47) | ABCB1ABCC1ABCG2DHFRREV1 | |
| SCHEMBL13662940 | 0.75 | ABCB1 (0.61) | ABCB1ABCC1ABCG2KMT2AREV1 | |
| SCHEMBL31013956 | 0.74 | DHFR (0.46) | ABCB1ABCC1ABCG2DHFRREV1 | |
| SCHEMBL25690710 | 0.74 | MAOA (0.46) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL28144681 | 0.74 | DHFR (0.48) | ABCB1ABCC1ABCG2DHFRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250108123-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
| US-20240199548-A1 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-06-20 | — | — | US | disclosed |
| WO-2024032782-A1 | VACCINE ADJUVANTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO.LTD. (CN) | 2024-02-15 | — | — | WO | disclosed |
| EP-4313946-A1 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2024-02-07 | — | — | EP | disclosed |
| CN-117242056-A | Novel compounds useful as STING agonists and uses thereof | 北京加科思新药研发有限公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2023109942-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109942-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2022199677-A1 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022199677-A1 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199548-A1 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | STING1, IRF3, CGAS | ABCB1 3692/4885ABCC1 2774/4885ABCG2 1902/4885 |
| US-20250108123-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | STING1, IRF3, CGAS | ABCB1 1682/4885ABCC1 2092/4885ABCG2 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.